Prevention and Treatment of Monkeypox

被引:384
作者
Rizk, John G. [1 ]
Lippi, Giuseppe [2 ]
Henry, Brandon M. [3 ]
Forthal, Donald N. [4 ,5 ]
Rizk, Youssef [6 ]
机构
[1] Univ Maryland, Sch Pharm, Dept Pharmaceut Hlth Serv Res, 220 Arch St,12th Floor,Room 01-409-E, Baltimore, MD 21201 USA
[2] Univ Verona, Sect Clin Biochem, Verona, Italy
[3] Cincinnati Childrens Hosp Med Ctr, Heart Inst, Cincinnati, OH 45229 USA
[4] Univ Calif Irvine, Sch Med, Dept Med, Div Infect Dis, Irvine, CA 92717 USA
[5] Univ Calif Irvine, Dept Mol Biol & Biochem, Sch Med, Irvine, CA 92717 USA
[6] Lebanese Amer Univ, Dept Internal Med, Div Family Med, Sch Med, Beirut, Lebanon
关键词
SMALLPOX; REEMERGENCE; SAFETY; VIRUS; RISK;
D O I
10.1007/s40265-022-01742-y
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Human monkeypox is a zoonotic orthopoxvirus with presentation similar to smallpox. Monkeypox is transmitted incidentally to humans when they encounter infected animals. Reports have shown that the virus can also be transmitted through direct contact (sexual or skin-to-skin), respiratory droplets, and via fomites such as towels and bedding. Multiple medical countermeasures are stockpiled for orthopoxviruses such as monkeypox. Two vaccines are currently available, JYNNEOS (TM) (live, replication incompetent vaccinia virus) and ACAM2000 (R) (live, replication competent vaccinia virus). While most cases of monkeypox will have mild and self-limited disease, with supportive care being typically sufficient, antivirals (e.g. tecovirimat, brincidofovir, cidofovir) and vaccinia immune globulin intravenous (VIGIV) are available as treatments. Antivirals can be considered in severe disease, immunocompromised patients, pediatrics, pregnant and breastfeeding women, complicated lesions, and when lesions appear near the mouth, eyes, and genitals. The purpose of this short review is to describe each of these countermeasures.
引用
收藏
页码:957 / 963
页数:7
相关论文
共 43 条
  • [11] [Anonymous], MONKEYPOX MULTIPLE C
  • [12] [Anonymous], US MONKEYPOX CASE
  • [13] [Anonymous], 2007, ACAM2000
  • [14] [Anonymous], VACCINES SMALLPOX
  • [15] Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections
    Baker, R
    Bray, M
    Huggins, JW
    [J]. ANTIVIRAL RESEARCH, 2003, 57 (1-2) : 13 - 23
  • [16] Centers for Disease Control and Prevention, WHAT CLIN NEED KNOW
  • [17] Short-term clinical safety profile of brincidofovir: A favorable benefit-risk proposition in the treatment of smallpox
    Chittick, Greg
    Morrison, Marion
    Brundage, Thomas
    Nichols, W. Garrett
    [J]. ANTIVIRAL RESEARCH, 2017, 143 : 269 - 277
  • [18] Crum-Cianflone NF, 2017, INFECT DIS THER, V6, P333, DOI 10.1007/s40121-017-0165-y
  • [19] THE TRANSMISSION POTENTIAL OF MONKEYPOX VIRUS IN HUMAN-POPULATIONS
    FINE, PEM
    JEZEK, Z
    GRAB, B
    DIXON, H
    [J]. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 1988, 17 (03) : 643 - 650
  • [20] GROSENBACH D, 2018, NEW ENGL J MED